Formae, Inc. develops CyborGel®, an investigational synthetic hydrogel cartilage implant system for minimally invasive knee resurfacing in progressive and post-traumatic osteoarthritis. Founded by orthopedic surgeon Kevin Mansmann, M.D., the company brings together medical, engineering, additive-manufacturing and entrepreneurial experience built through more than 25 years of research and development. CyborGel has received FDA Breakthrough Device Designation and remains limited to preclinical use while regulatory submissions and medical trials continue.
FDA Breakthrough Device Designation
Compliance program